Moderna Stock Rockets 34% With 5-Day Winning Streak
Moderna (MRNA) – a developer of mRNA-based therapeutics and vaccines – hit a 5-day winning streak, with cumulative gains over this period amounting to 34%. The company’s market cap has surged by about $6.2 Bil over the last 5 days and currently stands at $24 Bil.
Is this an opportunity or a trap? There are several things to fear in MRNA stock given its overall Weak operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Very Unattractive (For details, see Buy or Sell MRNA).
But here is the interesting part. You are reading about this 34% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Is IVV’s Growth Engine Worth The Price Of Admission?
- Does Constellation Energy Stock’s Surge Broaden Your Portfolio Or Just Amplify It?
- Google Has The Best Problem Money Can’t Quite Buy
- How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story
- Who Really Powered VGT’s Climb This Year?
- Is The AI Super-Cycle Real Enough To Bet On Micron Stock?
The following table summarizes the return for MRNA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MRNA | S&P 500 |
|---|---|---|
| 1D | 11.6% | -1.2% |
| 5D (Current Streak) | 34.4% | 2.1% |
| 1M (21D) | 28.5% | 0.2% |
| 3M (63D) | 17.9% | 12.0% |
| YTD 2026 | 109.6% | 8.4% |
| 2025 | -29.1% | 16.4% |
| 2024 | -58.2% | 23.3% |
| 2023 | -44.6% | 24.2% |
However, big gains can follow sharp reversals – but how has MRNA behaved after prior drops? See MRNA Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 30 S&P constituents with 3 days or more of consecutive gains and 115 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 6 | 92 |
| 4D | 2 | 16 |
| 5D | 21 | 3 |
| 6D | 0 | 2 |
| 7D or more | 1 | 2 |
| Total >=3 D | 30 | 115 |
Key Financials for Moderna (MRNA)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $3.2 Bil | $1.9 Bil |
| Operating Income | $-3.9 Bil | $-3.1 Bil |
| Net Income | $-3.6 Bil | $-2.8 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $676.0 Mil | $389.0 Mil |
| Operating Income | $-857.0 Mil | $-1.4 Bil |
| Net Income | $-826.0 Mil | $-1.3 Bil |
While MRNA stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.